Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 29, 2019
PolarityTE Names Board Member David Seaburg as President of Corporate Development
SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc.(PTE) announced today that David Seaburg will join the Company in the newly-created role of President ...
January 29, 2019
Inspire Medical Systems, Inc. Announces FDA Approval of New Sensing Lead
MINNEAPOLIS, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
January 28, 2019
Nicox Establishes High-Profile Glaucoma Clinical Advisory Board
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the formation of Nicox Glaucoma Clinical Advisory Board, composed of key clinical investigators ...
January 28, 2019
Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced publications expanding on previously reported results from three of the company’s ...
January 28, 2019
electroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference
BASKING RIDGE, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive Officer, Frank Amato and ...
January 28, 2019
Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that data from the ...
January 28, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase ...
January 24, 2019
Changes to Zealand Pharma’s Executive Management
Copenhagen, Denmark, January 23, 2019 – Zealand Pharma A/S today announced changes to its Executive Management. Following the resignation of Britt Meelby Jensen on 26 ...
January 24, 2019
HTG Molecular Appoints Dr. Joseph Sparano as Lead of Its Clinical Scientific Advisory Board for Breast Cancer Program
TUCSON, Ariz., Jan. 23, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
January 24, 2019
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on ...
January 24, 2019
Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer
Basel, Switzerland, January 24, 2019 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore ...
January 24, 2019
AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China
GARDEN CITY, N.Y. and REHOVOT, Israel, Jan. 24, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
January 24, 2019
Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc.’s (ARQL) partner, Basilea Pharmaceutica Ltd. (SIX:BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore ...
January 24, 2019
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
SALT LAKE CITY, Jan. 24, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application ("IND") ...
January 24, 2019
InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent
TEL AVIV, Israel, Jan. 24, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
January 8, 2019
Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
January 8, 2019
electroCore Announces Two New Studies and a Publication Supporting the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
BASKING RIDGE, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding ...
January 3, 2019
Cormedix Announces Closing of $7.5 Million Senior Secured Convertible Debt Financing
BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 3, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
January 3, 2019
Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
IRVING, Texas, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase ...
January 3, 2019
Chiasma Previews Important Upcoming Milestones
WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and ...
Page 49 of 169